The Klebsiella Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Klebsiella Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Klebsiella Infections. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Klebsiella Infections and features dormant and discontinued products.

GlobalData tracks 74 drugs in development for Klebsiella Infections by 66 companies/universities/institutes. The top development phase for Klebsiella Infections is preclinical with 48 drugs in that stage. The Klebsiella Infections pipeline has 62 drugs in development by companies and 12 by universities/ institutes. Some of the companies in the Klebsiella Infections pipeline products market are: Pedanius Therapeutics, ContraFect and Akthelia Pharmaceuticals.

The key targets in the Klebsiella Infections pipeline products market include UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase (UDP-3-O-Acyl-N-Acetylglucosamine Deacetylase or Protein EnvA or lpxC or EC, Bacterial Cell Wall, and Bacterial Cell Membrane.

The key mechanisms of action in the Klebsiella Infections pipeline product include UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase (UDP-3-O-Acyl-N-Acetylglucosamine Deacetylase or Protein EnvA or lpxC or EC Inhibitor with three drugs in Preclinical. The Klebsiella Infections pipeline products include seven routes of administration with the top ROA being Oral and 16 key molecule types in the Klebsiella Infections pipeline products market including Small Molecule, and Biologic.

Klebsiella Infections overview

Klebsiella infections are caused by bacteria of the genus Klebsiella, with K. pneumoniae being the most common species associated with human infections. These bacteria are part of the normal flora in the human digestive tract and respiratory system but can cause various infections, especially in individuals with weakened immune systems or underlying health conditions. Klebsiella infections can manifest in different parts of the body, leading to various clinical presentations. K. pneumoniae is notorious for causing a severe form of pneumonia, particularly in hospitalized patients, elderly individuals, or those with chronic lung diseases. Symptoms include high fever, coughing, difficulty breathing, and in some cases, coughing up blood.

For a complete picture of Klebsiella Infections’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.